Latest Healthcare Research Reports

Tag: cell and gene therapy market trends

  • Cell And Gene Therapy Clinical Trial Services Market to Reach $6.22 Billion by 2029 | Key Drivers and Future Outlook

    Cell And Gene Therapy Clinical Trial Services Market to Reach $6.22 Billion by 2029 | Key Drivers and Future Outlook

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Is the Estimated Market Size of the Cell And Gene Therapy Clinical Trial Services Market In 2029?

    The market size for clinical trial services in cell and gene therapy has experienced swift growth in recent years. It is projected to expand from $3.79 billion in 2024 to reach $4.2 billion in 2025, marking a Compound Annual Growth Rate (CAGR) of 10.7%. The acceleration in growth during this historic period is linked to factors such as the higher frequency of chronic ailments, rising demand for efficient treatments for uncommon genetic maladies, enhanced governmental funding for regenerative medicine research, improved comprehension of molecular procedures related to various diseases, and growing awareness about the prospects of personalized medicine.

    What Growth Rate Is Forecasted for the Cell And Gene Therapy Clinical Trial Services Market by 2029?

    Over the next few years, rapid expansion is anticipated in the market for cell and gene therapy clinical trial services. With a compound annual growth rate (CAGR) of 10.3%, the market is projected to reach $6.22 billion by 2029. The rise in genetic and auto-immune disease cases worldwide, increased funding by the public and private sectors for gene therapy research, new technology utilization, and a surge in genetic defects are all contributing factors to the growth during this forecast period. Key trends expected in this period include the use of artificial intelligence, machine learning adoption, personalized medicine, technological advancements, and gene therapies.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=15535&type=smp

    Which Key Companies Are Shaping the Future of the Cell And Gene Therapy Clinical Trial Services Market?

    Major companies operating in the cell and gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, IQVIA, Laboratory Corporation of America Holdings, ICON plc, Syneos Health Inc., Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Parexel International Corporation, PRA Health Sciences Inc., Covance Inc., Medpace Holdings Inc., BioClinica Inc., Precision Medicine Group LLC, Worldwide Clinical Trials LLC, Clinigen Group plc, Evidera Inc., Advarra LLC, Veristat LLC, Clinipace Inc., Celonic AG, Cromsource Inc., Novotech Pty Ltd., MedSource Holdings Inc., Frontage Laboratories Inc.

    Which Factors Are Driving Demand in the Cell And Gene Therapy Clinical Trial Services Industry?

    The growth of the cell and gene therapy clinical trial services market is anticipated to be driven by the increasing prevalence of genetic disorders. These disorders stem from changes in an individual’s DNA or genetic make-up. Factors contributing to the surge in genetic disorders include the rise in genetic testing availability, genetic mutations occurrence, and the high rate of consanguineous marriages. This rising trend of genetic diseases is being tackled by the cell and gene therapy clinical trial services market by promoting innovative treatment development, personalizing treatments for each patient, hastening research conversion into clinical applications, and broadening the treatment prospects for patients with genetic conditions. For example, the Cystic Fibrosis (CF) Foundation, a not-for-profit organization based in the US, reported a substantial increase in the cystic fibrosis affected population in July 2022. In 2022, approximately 40,000 children and adults in the US were affected by cystic fibrosis, and globally, over 105,000 people were diagnosed. Hence, the escalating prevalence of genetic disorders is fuelling the cell and gene therapy clinical trial services market’s expansion.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=15535&type=smp

    How Is the Cell And Gene Therapy Clinical Trial Services Market Segmented by Several Divisions?

    The cell and gene therapy clinical trial services market covered in this report is segmented –

    1) By Service: Clinical Trial Design And Planning, Supply And Logistic Services, Regulatory Affairs And Compliance, Data Management And Biostatics, Site Management And Monitoring, Other Services

    2) By Therapy Type: Gene Therapy, Cell Therapy, Gene Modified Cell Therapy

    3) By Indication: Oncology, Hematology, Metabolic Disorders, Infectious Diseases, Neurology, Cardiovascular Diseases, Musculoskeletal Disorders, Other Indications

    4) By End-Use: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic And Research Institutes, Other End-Users

    Subsegments:

    1) By Clinical Trial Design And Planning: Protocol Development, Trial Feasibility Studies, Trial Design Consultation, Patient Recruitment And Enrollment Strategy, Risk-Based Monitoring Plans

    2) By Supply And Logistic Services: Clinical Trial Supply Chain Management, Cold Chain Logistics, Packaging And Labeling Services, Transportation And Distribution Of Biological Samples, Customs And Import/Export Services

    3) By Regulatory Affairs And Compliance: Regulatory Strategy And Consulting, Regulatory Submission And Documentation, Compliance With GMP (Good Manufacturing Practices), Regulatory Pathway Consultation, Clinical Trial Applications (CTAs)

    4) By Data Management And Biostatistics: Clinical Data Management (CDM), Statistical Analysis And Reporting, Clinical Data Monitoring, Data Integration And Validation, Electronic Data Capture (EDC) Solutions

    5) By Site Management And Monitoring: Site Selection And Initiation, Clinical Monitoring And Site Visits, Patient Recruitment And Retention, Site Training And Support, Site Performance Monitoring

    6) By Other Services: Patient Advocacy And Engagement, Real-World Evidence (RWE) Studies, Post-Trial Services, Medical Writing And Documentation, Clinical Trial Auditing And Inspection

    What are the Emerging Market Trends Driving the Growth of the Cell And Gene Therapy Clinical Trial Services Industry?

    Leading corporations in the cell and gene therapy clinical trial services market are diversifying their strategies by implementing cutting-edge technology and customer relationship management system technology to enhance productivity and gain an upper hand in the competitive market. The customer relationship management system used by these services enhances the communication and interaction with trial participants, healthcare providers, and other involved parties during the clinical trial phase. For example, in April 2023, AmerisourceBergen Corporation, a healthcare firm based in the US, inaugurated the Cell and Gene Therapy (CGT) Integration Hub. This platform aims to augment connectivity and simplify processes throughout the cell and gene therapy treatment journey. Supported by AmerisourceBergen’s customer relationship management (CRM) system, it aims to streamline the care pathway by offering physicians and patient services teams increased transparency throughout therapy development and delivery. The CGT Integration Hub, equipped with features such as fast-tracked benefits investigation, real-time status updates, and preemptive alerts, is designed to simplify care coordination, reduce obstacles, and enhance the experience for patients and providers throughout the delivery of cell and gene therapies.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

    Which Regions Are Driving Growth in the Cell And Gene Therapy Clinical Trial Services Market?

    North America was the largest region in the cell and gene therapy clinical trial services market in 2023. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15535

    This Report Delivers Insight On:

    1. How big is the cell and gene therapy clinical trial services market, and how is it changing globally?

    2. Who are the major companies in the cell and gene therapy clinical trial services market, and how are they performing?

    3. What are the key opportunities and risks in the cell and gene therapy clinical trial services market right now?

    4. Which products or customer segments are growing the most in the cell and gene therapy clinical trial services market?

    5. What factors are helping or slowing down the growth of the cell and gene therapy clinical trial services market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 2071930708

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Cell and Gene Therapy Forecast Report – Designed for Decision Makers and Product Teams

    Cell and Gene Therapy Forecast Report – Designed for Decision Makers and Product Teams

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    #What Is the Growth Rate of the Cell and Gene Therapy Market?#_x000D_

    The market size for cell and gene therapy has witnessed massive expansion in the past few years. It is projected to escalate from $12.01 billion in 2024 to $15.48 billion in 2025, with a compound annual growth rate (CAGR) of 28.9%. This growth during the historical period can be ascribed to the surge in investments towards cell and gene therapies, advancements in the research and development sector, progress in cancer drug discovery, an increase in public-private collaborations, robust economic development in emerging markets, enhanced healthcare spending and an upsurge in expenditure dedicated to pharmaceutical R&D._x000D_

    _x000D_

    #What Growth Rate Is Forecasted for the Cell and Gene Therapy Market by 2029?#_x000D_

    The dimension of the cell and gene therapy market is set to witness impressive expansion in the upcoming years, ballooning up to $29.15 billion in 2029, demonstrating an annual compound growth rate of 17.1%. Factors contributing to growth during the forecast period include the growing instances of chronic diseases and prevailing cancer, an increase in the elderly population, and a heightened interest in cell and gene therapies, as well as escalated spending in healthcare. Key trends projected for the period of forecast include prioritization of advanced treatments such as chimeric antigen receptor (CAR) T-cell, substantial investment in research and securing funding, implementing strategic partnerships to incorporate state-of-the-art technologies, focusing on the construction of gene or genome editing tools, especially CRISPR, merger or acquisition of competitor firms, stepping up the volume of studies in the pipeline to create novel cell and gene therapies, and putting funds into the extension of manufacturing facilities._x000D_

    _x000D_

    #Download The Free Sample Report Here:#_x000D_

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp_x000D_

    _x000D_

    #Which Key Companies Are Shaping the Future of the Cell and Gene Therapy Market?#_x000D_

    Major companies operating in the cell and gene therapy market include Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Biocon, Cipla, Stempeutics Research Pvt. Ltd., EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Oxford Biomedica plc, Santen Pharmaceutical Co., Therapeutic Innovation Australia, Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, inStem, Lonza, Nikon CeLL innovation Co. Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Oxford BioTherapeutics, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca_x000D_

    _x000D_

    #Which Factors Are Driving Demand in the Cell and Gene Therapy Industry?#_x000D_

    The cell and gene therapy (CGT) market has experienced significant growth due to consistent investments and consolidation within the cell and gene therapy fields. Recognizing the potential of the CGT market, 80% of the top 20 biopharmaceutical companies in terms of revenue have added CGT products to their portfolio. Specifically, in 2023, the BioIndustry Association (BIA), a UK-based life sciences and biotech industry representative body, reported that UK cell and gene therapy companies claimed more than half of the venture capital funding gained by European firms. Typically, the UK accounts for approximately a third of all European venture capital investments in the life sciences sector, which emphasizes the strength of their cell and gene therapy sector. Constant investment and consolidation in CGT production have resulted in increased production capacity and market growth. For instance, in October 2024, Purespring Therapeutics, a UK-based biotech firm, secured $105 million in funding to back the development of gene therapies for kidney diseases, including a phase 1/2 trial of an experimental treatment for immunoglobulin A nephropathy (IgAN). Purespring uses adeno-associated viruses (AAVs) to administer its gene therapies._x000D_

    _x000D_

    #Request For A Customized Report:#_x000D_

    https://www.thebusinessresearchcompany.com/customise?id=3472&type=smp_x000D_

    _x000D_

    #How Is the Cell and Gene Therapy Market Segmented by Several Divisions?#_x000D_

    The cell and gene therapy market covered in this report is segmented –_x000D_

    _x000D_

    1) By Product: Cell Therapy, Gene Therapy_x000D_

    2) By Application: Oncology, Neurological Disorders, Other Applications_x000D_

    3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users_x000D_

    _x000D_

    Subsegments:_x000D_

    1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy_x000D_

    2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy_x000D_

    _x000D_

    _x000D_

    #What are the Emerging Market Trends Driving the Growth of the Cell and Gene Therapy Industry?#_x000D_

    The cell and gene therapy (CGT) market is being significantly influenced by the rise of Chimeric antigen receptor (CAR) T-cell therapy. This therapy involves a combination of cell and gene therapy, where specialized T cells are gathered from the patient’s blood, and then genetically tinkered to generate modified receptors on their surfaces, recognized as chimeric antigen receptors (CARs). These altered T cells, equipped with particular constructs (receptors), are reintroduced into the patient. Subsequently, these re-engineered receptors on the T cells facilitate the targeting of the cancer cell’s surface antigen, culminating in the elimination of tumorous cells in the affected patients. As an example, in June 2022, the US-based pharmaceutical firm, Bristol-Myers Squibb Company, successfully gained approval from the United States Food and Drug Administration (US FDA) for their CAR T cell therapy named Breyanzi. This therapy is intended for treating adult patients suffering from large B-cell lymphoma (LBCL), which includes conditions like diffuse large B-cell lymphoma. Breyanzi is a distinct CAR T cell therapy, created from a patient’s own T cells, which are harvested and genetically reprogrammed into CAR T cells, then reintroduced into the patient through infusion as a one-time treatment._x000D_

    _x000D_

    #Access The Full Report Here:#_x000D_

    https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report_x000D_

    _x000D_

    #Which Regions Are Driving Growth in the Cell and Gene Therapy Market?#_x000D_

    North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

    _x000D_

    #Purchase The Full Report Today:#_x000D_

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3472_x000D_

    _x000D_

    #This Report Delivers Insight On: #_x000D_

    1. How big is the cell and gene therapy market, and how is it changing globally?_x000D_

    2. Who are the major companies in the cell and gene therapy market, and how are they performing?_x000D_

    3. What are the key opportunities and risks in the cell and gene therapy market right now?_x000D_

    4. Which products or customer segments are growing the most in the cell and gene therapy market?_x000D_

    5. What factors are helping or slowing down the growth of the cell and gene therapy market?_x000D_

    _x000D_

    #About The Business Research Company:#_x000D_

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

    _x000D_

    #Get in touch with us:#_x000D_

    The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

    Americas +1 310-496-7795_x000D_

    Asia +44 2071930708_x000D_

    Europe +44 7882 955267_x000D_

    Email us at info@tbrc.info_x000D_

    _x000D_

    #Follow us on:#_x000D_

    _x000D_

    LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Emerging Trends Redefining the CC Chemokine Receptor Type 5 Market Landscape: Innovative Solutions In Cell And Gene Therapy Clinical Trial Services Market

    Emerging Trends Redefining the CC Chemokine Receptor Type 5 Market Landscape: Innovative Solutions In Cell And Gene Therapy Clinical Trial Services Market

    Discover trends, market shifts, and competitive outlooks for the cell and gene therapy clinical trial services industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

    What is the Anticipated CAGR of the Cell And Gene Therapy Clinical Trial Services Market, and What Factors Will Drive It?

    The market for cell and gene therapy clinical trial services have experienced swift expansion in the past few years. The increase from $3.79 billion in 2024 to $4.2 billion in 2025 is expected, reflecting a compound annual growth rate (CAGR) of 10.7%. The historic rise can be linked to the growing incidences of chronic illnesses, heightened need for effective treatments for rare genetic disorders, enhanced government support for regenerative medicine research, improved comprehension of molecular mechanisms related to several diseases and a raised consciousness about the capabilities of personalized medicine.

    The market size of clinical trial services for cell and gene therapy is anticipated to witness significant growth in the ensuing years. It is projected to reach $6.22 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.3%. The growth for the prediction period is linked to the rising worldwide prevalence of genetic and auto-immune diseases, increased funding for gene therapy research from both the public and private sectors, wider acceptance of groundbreaking technologies and an increase in the count of genetic defects. Key trends during the forecasted period encompass the incorporation of AI, the implementation of machine learning, the introduction of customized medicine, technological advancements, as well as gene therapies.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=15535&type=smp

    What Are the Core Market Drivers Propelling Growth in the Cell And Gene Therapy Clinical Trial Services Industry?

    The escalation in cases of genetic disorders is forecasted to spur the expansion of the cell and gene therapy clinical trial services market. Genetic disorders are conditions brought on by alterations in an individual’s DNA or genetic make-up. Several reasons, including the increasing accessibility of genetic testing, the appearance of genetic mutations, and the commonality of consanguineous marriages are responsible for the surge in genetic diseases. Cell and gene therapy clinical trial services aim to address the escalation of genetic disorders by promoting the creation of innovative treatments, personalizing therapies for each patient, expediting the application of research into clinical use, and broadening the selection of treatments for those affected by genetic ailments. For instance, the Cystic Fibrosis (CF) Foundation, a non-profit organization based in the US, reported a surge in cystic fibrosis cases in July 2022. In 2022, cystic fibrosis impacted nearly 40,000 children and adults in the United States, and over 105,000 people globally have been diagnosed. Consequently, the escalation in genetic disorders is contributing to the expansion of the cell and gene therapy clinical trial services market.

    How Is the Cell And Gene Therapy Clinical Trial Services Market Segmented?

    The cell and gene therapy clinical trial services market covered in this report is segmented –

    1) By Service: Clinical Trial Design And Planning, Supply And Logistic Services, Regulatory Affairs And Compliance, Data Management And Biostatics, Site Management And Monitoring, Other Services

    2) By Therapy Type: Gene Therapy, Cell Therapy, Gene Modified Cell Therapy

    3) By Indication: Oncology, Hematology, Metabolic Disorders, Infectious Diseases, Neurology, Cardiovascular Diseases, Musculoskeletal Disorders, Other Indications

    4) By End-Use: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic And Research Institutes, Other End-Users

    Subsegments:

    1) By Clinical Trial Design And Planning: Protocol Development, Trial Feasibility Studies, Trial Design Consultation, Patient Recruitment And Enrollment Strategy, Risk-Based Monitoring Plans

    2) By Supply And Logistic Services: Clinical Trial Supply Chain Management, Cold Chain Logistics, Packaging And Labeling Services, Transportation And Distribution Of Biological Samples, Customs And Import/Export Services

    3) By Regulatory Affairs And Compliance: Regulatory Strategy And Consulting, Regulatory Submission And Documentation, Compliance With GMP (Good Manufacturing Practices), Regulatory Pathway Consultation, Clinical Trial Applications (CTAs)

    4) By Data Management And Biostatistics: Clinical Data Management (CDM), Statistical Analysis And Reporting, Clinical Data Monitoring, Data Integration And Validation, Electronic Data Capture (EDC) Solutions

    5) By Site Management And Monitoring: Site Selection And Initiation, Clinical Monitoring And Site Visits, Patient Recruitment And Retention, Site Training And Support, Site Performance Monitoring

    6) By Other Services: Patient Advocacy And Engagement, Real-World Evidence (RWE) Studies, Post-Trial Services, Medical Writing And Documentation, Clinical Trial Auditing And Inspection

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=15535&type=smp

    Which Regions Are Driving the Next Phase of the Cell And Gene Therapy Clinical Trial Services Market Growth?

    North America was the largest region in the cell and gene therapy clinical trial services market in 2023. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Are the Key Market Trends in the Cell And Gene Therapy Clinical Trial Services Market Over the Coming Years?

    Leading enterprises in the cell and gene therapy clinical trial services market are directing their resources towards the incorporation of high-tech customer relationship management system technology to enhance efficiency and gain a competitive advantage. The cell and gene therapy clinical trial services use these systems to efficiently coordinate and manage interactions with trial participants, healthcare providers, and other involved parties throughout the clinical trial procedure. For example, in April 2023, the US healthcare company AmerisourceBergen Corporation launched the Cell and Gene Therapy (CGT) Integration Hub. This platform, designed to improve connectivity and streamline operations throughout the cell and gene therapy treatment pathway, is powered by AmerisourceBergen’s CRM system. Its aim is to simplify the journey to treatment by providing physicians and patient services teams with a clearer picture of the therapy development and delivery process. The CGT Integration Hub, which comes with features like accelerated benefits investigation, real-time status tracking, and proactive alerts, aspires to simplify care coordination, reduce obstacles, and enhance the overall experience of patients and providers when administering cell and gene therapies.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

    How Is the Cell And Gene Therapy Clinical Trial Services Market Defined and What Are Its Core Parameters?

    Cell and gene therapy clinical trial services refer to specialized services offered by contract research organizations (CROs) or clinical trial management corporations to facilitate the design, implementation, and management of clinical trials for cell and gene therapies. These services, which range from protocol design and patient recruiting to regulatory compliance and data administration, serve as the foundation for trials to progress smoothly, ensuring precision, efficacy, and adherence to high standards.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15535

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Cell and Gene Therapy Market Insights: In-Depth Look at Growth Trends, Market Size, and Opportunities for 2025-2034

    Cell and Gene Therapy Market Insights: In-Depth Look at Growth Trends, Market Size, and Opportunities for 2025-2034

    Discover trends, market shifts, and competitive outlooks for the cell and gene therapy industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

    #What is the Anticipated CAGR of the Cell and Gene Therapy Market, and What Factors Will Drive It?

    The market size for cell and gene therapy has seen a remarkable increase in the recent past. It is projected to surge from a market value of $12.01 billion in 2024 to a staggering $15.48 billion in 2025, reflecting a compound annual growth rate (CAGR) of 28.9%. Various factors like increased investment in cell and gene therapy, enhanced research and development activities, progress in cancer drug innovation, an upswing in public and private sector collaborations, robust economic growth witnessed in budding markets, augmented healthcare spending, and a rise in expenditure on pharmaceutical research and development contribute to the growth observed in the historic period.

    Swift expansion is predicted for the cell and gene therapy market, which is projected to rise to $29.15 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 17.1%. This surge over the forecast period can be credited to factors such as the growing incidence of cancer and chronic illnesses, an increasing elderly population, heightened focus on cell and gene therapy, and upsurge in healthcare spending. Key trends expected during the forecast period encompass emphasis on sophisticated therapies like chimeric antigen receptor (CAR) T-cell therapy, dedication towards various research endeavors and securing funding, executing strategic collaborations to amalgamate cutting-edge technologies, focus on the creation of gene or genome editing instruments, particularly CRISPR, forming partnerships or takeover of rival firms, elevating the count of pipeline investigations to devise cell and gene therapies, and investment in the expansion of manufacturing facilities.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

    What External and Internal Drivers Are Contributing to the Growth of theCell and Gene Therapy Market?

    Investment stability and amalgamation played key roles in the development of the cell and gene therapy (CGT) market. The potential of the CGT market was realized by 16 of the top 20 revenue-earning biopharmaceutical firms, all of which introduced CGT products into their offerings. The BioIndustry Association (BIA), a UK-based entity that represents the biotech and life sciences industries, noted that in 2023, over 55% of venture capital secured by European enterprises was obtained by UK cell and gene therapy corporations. Typically, the UK is responsible for approximately one third of all European venture capital investments in life sciences, demonstrating the prominence of its CGT sector. The CGT manufacturing capacity has seen stable investments and collaboration, resulting in an amplified production capacity, thus fostering market expansion. To illustrate, in October 2024, Purespring Therapeutics, a UK biotech firm, secured $105 million in funding to assist in the development of gene therapies for kidney diseases, including a phase 1/2 experimental treatment trial for immunoglobulin A nephropathy (IgAN). Adeno-associated viruses (AAVs) are employed by Purespring to deliver its gene therapies to the body.

    What Segment Types Define the Cell and Gene Therapy Market Structure?

    The cell and gene therapy market covered in this report is segmented –

    1) By Product: Cell Therapy, Gene Therapy

    2) By Application: Oncology, Neurological Disorders, Other Applications

    3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

    Subsegments:

    1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy

    2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=3472&type=smp

    Which Geographic Areas Hold the Strongest Growth Potential in the Cell and Gene Therapy Market?

    North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    What Long-Term Trends Are Transforming the Competitive Landscape of the Cell and Gene Therapy Market?

    The cell and gene therapy (CGT) market is being revolutionized by Chimeric antigen receptor (CAR) T-cell therapy. This therapeutic approach involves collecting T cells from a patient’s blood, genetically engineering them to develop chimeric antigen receptors (CARs) – a type of modified receptor, and reintroducing these modified T cells back into the patient. These reengineered T cells, possessing unique receptor structures, aid in identifying and targeting cancer cell surface antigens, ultimately leading to the destruction of tumor cells. For example, in June 2022, Bristol-Myers Squibb Company, a US pharmaceutical firm, gained approval from the United States Food and Drug Administration (US FDA) for its CAR T cell therapy Breyanzi. This approval was for treating adult patients suffering from large B-cell lymphoma (LBCL), including the diffuse large B-cell lymphoma. Breyanzi is a unique CAR T cell therapy that uses a patient’s own T cells, which undergo collection and re-engineering to become CAR T cells for reintroduction into the patient as a single-administration treatment.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

    What Is the Definition of the Cell and Gene Therapy Market?

    Gene therapy involves the transmission of genetic material, typically in the form of a carrier or vector, and the uptake of the gene into the proper body cells. Cell therapy includes introducing cells into the patient with the appropriate function. Some procedures combine cell therapy with gene therapy.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3472

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • The Future of the CC Chemokine Receptor Type 5 Market: Growth Trends, Market Size, and Opportunities to Watch

    The Future of the CC Chemokine Receptor Type 5 Market: Growth Trends, Market Size, and Opportunities to Watch

    2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

    What Industry-Specific Factors Are Fueling the Growth of theCell And Gene Therapy Clinical Trial Services Market?

    The cell and gene therapy clinical trial services market is set to be propelled by the increasing occurrence of genetic diseases. These include conditions arising from variations in an individual’s genetic makeup or DNA. The surge in genetic diseases can be attributed to multiple reasons such as greater accessibility to genetic testing, instances of genetic mutations, and the prominence of marriages between close relatives. To address the mounting prevalence of genetic diseases, cell and gene therapy clinical trial services are promoting the creation of new treatments, adjusting therapies to suit individual patients’ needs, hastening the conversion of research into clinical applications and broadening the choices for patients with genetic disorders. For example, in July 2022, the Cystic Fibrosis (CF) Foundation, a not-for-profit organization based in the United States, reported a hike in the prevalence of people suffering from cystic fibrosis; around 40,000 children and adults in the United States and more than 105,000 people worldwide were affected by the disease in 2022. Thus, the rising occurrence of genetic diseases is fuelling the expansion of the cell and gene therapy clinical trial services market.

    Get Your Free Sample Report Now – Explore Exclusive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=15535&type=smp

    #What is the Anticipated CAGR of theCell And Gene Therapy Clinical Trial Services Market, and What Factors Will Drive It?

    Over the past few years, the market size for clinical trial services for cell and gene therapy has seen a significant increase. The forecast suggests a rise from $3.79 billion in 2024, up to $4.2 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.7%. The prior growth can be attributed to factors such as the rising prevalence of long-term illnesses, heightened demand for efficacious treatments for rare genetic disorders, better government funding for regenerative medicine research, improved comprehension of the molecular mechanisms involved in various diseases, and enhanced recognition of personalized medicine’s potential.

    Expected to see a fast-paced expansion in the coming years, the market for cell and gene therapy clinical trial services is envisaged to reach a valuation of $6.22 billion in 2029, with a compound annual growth rate (CAGR) of roughly 10.3%. This growth over the predicted period can be ascribed to factors such as the escalating global occurrence of genetic and auto-immune diseases, the rise in public as well as private sector investment in gene therapy research, increased acceptance of new technologies, and a surge in the number of genetic defects. Key trends in the forecast phase encompass the incorporation of AI, the use of machine learning, the application of personalized medicine, technological advancements, and gene therapies.

    You can Directly Purchase the Report Here:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15535

    What Key Market Trends and Innovations Are Shaping the Future of theCell And Gene Therapy Clinical Trial Services Industry?

    Leading companies in the cell and gene therapy clinical trial services market are turning to sophisticated technology integrated with customer relationship management (CRM) systems in order to enhance their operational efficiency and secure a competitive edge. These CRM systems deployed by cell and gene therapy clinical trial services enhance coordination and streamline communication with trial participants, healthcare providers, and other relevant parties during the clinical trial process. For example, in April 2023, the healthcare firm AmerisourceBergen Corporation, based in the US, unveiled the Cell and Gene Therapy (CGT) Integration Hub. This platform is designed to boost connectivity and streamline procedures throughout the cell and gene therapy treatment pathway. Backed by AmerisourceBergen’s CRM system, the platform aims to simplify the path-to-care by providing doctors and patient services teams with improved oversight of the therapy development and delivery process. The CGT Integration Hub, equipped with features such as expedited benefits investigation, real-time status tracking, and proactive alerts, is designed to simplify care coordination, eliminate hurdles, and enhance the overall experience of patients and providers in the delivery of cell and gene therapies.

    Which Companies Are Leading the Charge in Expanding theCell And Gene Therapy Clinical Trial Services Market Growth?

    Major companies operating in the cell and gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, IQVIA, Laboratory Corporation of America Holdings, ICON plc, Syneos Health Inc., Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Parexel International Corporation, PRA Health Sciences Inc., Covance Inc., Medpace Holdings Inc., BioClinica Inc., Precision Medicine Group LLC, Worldwide Clinical Trials LLC, Clinigen Group plc, Evidera Inc., Advarra LLC, Veristat LLC, Clinipace Inc., Celonic AG, Cromsource Inc., Novotech Pty Ltd., MedSource Holdings Inc., Frontage Laboratories Inc.

    Order Your Report Now For A Swift Delivery:

    https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

    How is the Global Cell And Gene Therapy Clinical Trial Services Market Segemented?

    The cell and gene therapy clinical trial services market covered in this report is segmented –

    1) By Service: Clinical Trial Design And Planning, Supply And Logistic Services, Regulatory Affairs And Compliance, Data Management And Biostatics, Site Management And Monitoring, Other Services

    2) By Therapy Type: Gene Therapy, Cell Therapy, Gene Modified Cell Therapy

    3) By Indication: Oncology, Hematology, Metabolic Disorders, Infectious Diseases, Neurology, Cardiovascular Diseases, Musculoskeletal Disorders, Other Indications

    4) By End-Use: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic And Research Institutes, Other End-Users

    Subsegments:

    1) By Clinical Trial Design And Planning: Protocol Development, Trial Feasibility Studies, Trial Design Consultation, Patient Recruitment And Enrollment Strategy, Risk-Based Monitoring Plans

    2) By Supply And Logistic Services: Clinical Trial Supply Chain Management, Cold Chain Logistics, Packaging And Labeling Services, Transportation And Distribution Of Biological Samples, Customs And Import/Export Services

    3) By Regulatory Affairs And Compliance: Regulatory Strategy And Consulting, Regulatory Submission And Documentation, Compliance With GMP (Good Manufacturing Practices), Regulatory Pathway Consultation, Clinical Trial Applications (CTAs)

    4) By Data Management And Biostatistics: Clinical Data Management (CDM), Statistical Analysis And Reporting, Clinical Data Monitoring, Data Integration And Validation, Electronic Data Capture (EDC) Solutions

    5) By Site Management And Monitoring: Site Selection And Initiation, Clinical Monitoring And Site Visits, Patient Recruitment And Retention, Site Training And Support, Site Performance Monitoring

    6) By Other Services: Patient Advocacy And Engagement, Real-World Evidence (RWE) Studies, Post-Trial Services, Medical Writing And Documentation, Clinical Trial Auditing And Inspection

    Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

    https://www.thebusinessresearchcompany.com/customise?id=15535&type=smp

    Which Geographics are Influencing the Growth of the Cell And Gene Therapy Clinical Trial Services Market?

    North America was the largest region in the cell and gene therapy clinical trial services market in 2023. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Reports Similar to the Global Cell And Gene Therapy Clinical Trial Services Market 2025, By The Business Research Company:

    Cell Isolation Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/cell-isolation-global-market-report

    Cell Therapy Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

    Cell Lysis And Fractionation Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/cell-lysis-and-fractionation-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Top Growth Trends in the Cell and Gene Therapy Market: Insights into Market Size and Opportunities for 2025-2034

    Top Growth Trends in the Cell and Gene Therapy Market: Insights into Market Size and Opportunities for 2025-2034

    2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

    What External and Internal Drivers Are Contributing to the Growth of theCell and Gene Therapy Market?

    The cell and gene therapy (CGT) market has grown due to continuous investments and consolidations within cell and gene therapies. Recognizing the potential of this market, 16 of the top 20 big biopharmaceutical firms by revenue have included CGT products in their range. For example, in 2023, according to the BioIndustry Association (BIA), which is UK-based and represents the life sciences and biotech sector, cell and gene therapy companies from the UK secured more than half of venture capital investments received by European companies. Typically, the UK accounts for about a third of all European venture capital investments in life sciences, which underscores the strength of its cell and gene therapy industry. Continuous investments and mergers in CGT production capacity have resulted in increased production and further market growth. For example, in October 2024, Purespring Therapeutics, a UK-based biotechnology firm, received a funding of $105 million to support kidney disease gene therapies development, including a phase 1/2 trial of a new treatment for immunoglobulin A nephropathy (IgAN). Purespring uses adeno-associated viruses (AAVs) to deliver its gene therapies into the body.

    Get Your Free Sample Report Now – Explore Exclusive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

    #What is the Anticipated CAGR of theCell and Gene Therapy Market, and What Factors Will Drive It?

    In recent years, the cell and gene therapy market has experienced significant growth. It is projected to increase from a size of $12.01 billion in 2024 to a staggering $15.48 billion in 2025 with a compound annual growth rate (CAGR) of 28.9%. The historic surge in growth is driven by increased financial investment in cell and gene therapies, advancements in research and development, progress in the discovery of cancer drugs, an upswing in public-private collaborations, a robust economic upturn in developing markets, heightened healthcare costs, and an increase in expenditure on pharmaceutical research and development.

    Over the coming years, the cell and gene therapy market is predicted to experience swift expansion, with projections indicating that it will reach $29.15 billion by 2029. This growth corresponds to a compound annual growth rate (CAGR) of 17.1%. Factors contributing to this growth during the forecast period include growing cases of cancer and chronic illnesses, an increase in the aging population, heightened emphasis on cell and gene therapy, and healthcare expenditure increases. Key trends for the forecast period include placing emphasis on cutting-edge therapies such as chimeric antigen receptor (CAR) T-cell therapy, focusing on launching various research initiatives and securing funding, implementing strategic collaborations to incorporate advanced technology, focusing on the development of gene or genome editing tools especially CRISPR, merging with or acquiring rivals, upscaling the number of pipeline research to develop cell and gene therapies, and investment in expanding production facilities.

    You can Directly Purchase the Report Here:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3472

    Which Upcoming Market Trends and Innovations Are Set to Influence theCell and Gene Therapy Market’s Path Forward?

    The cell and gene therapy (CGT) market is being revolutionized by Chimeric antigen receptor (CAR) T-cell therapy. This therapy is a fusion of cell and gene therapy where T cells are modified with genetically engineered receptors, called Chimeric antigen receptors (CARs), after being collected from a patient’s blood. The modified T cells, now featuring specialized receptors, are then reintroduced into the patient’s body. These receptors aid in identifying and attacking cancer cells’ surface antigens, leading to the elimination of tumor cells. To illustrate, Bristol-Myers Squibb Company, an American pharmaceutical firm, got approval from the US Food and Drug Administration (US FDA) for its CAR T cell therapy Breyanzi in June 2022. This therapy is particularly meant for adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma. Breyanzi, a unique CAR T cell therapy, is fabricated from a patient’s T cells, which are collected, genetically altered into CAR T cells, and then infused back into the patient as a stand-alone treatment.

    Who Are the Dominant Market Players Pushing the Boundaries of theCell and Gene Therapy Market?

    Major companies operating in the cell and gene therapy market include Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Biocon, Cipla, Stempeutics Research Pvt. Ltd., EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Oxford Biomedica plc, Santen Pharmaceutical Co., Therapeutic Innovation Australia, Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, inStem, Lonza, Nikon CeLL innovation Co. Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Oxford BioTherapeutics, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca

    Order Your Report Now For A Swift Delivery:

    https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

    What Are the Core Segments of the Cell and Gene Therapy Market, and How Do They Contribute to Growth?

    The cell and gene therapy market covered in this report is segmented –

    1) By Product: Cell Therapy, Gene Therapy

    2) By Application: Oncology, Neurological Disorders, Other Applications

    3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

    Subsegments:

    1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy

    2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

    Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

    https://www.thebusinessresearchcompany.com/customise?id=3472&type=smp

    What Regions Are Dominating the Cell and Gene Therapy Market Growth?

    North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Browse Through More Reports Similar to the Global Cell and Gene Therapy Market 2025, By The Business Research Company:

    nucleic acid based gene therapy market, global nucleic acid based gene therapy market, nucleic acid based gene therapy market trends, nucleic acid based gene therapy market forecast, nucleic acid based gene therapy market analysis, nucleic acid-based therapeutics market, nucleic acid based gene therapy global market report 2021, nucleotide therapy market, gene therapy industry report, nucleic acid based gene therapy market report 2020

    https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market

    Alpha Mannosidosis Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report

    Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2031

    https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-market

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • In-Depth Insights into the Cell And Gene Therapy Clinical Trial Services Market: Growth, Trends, and Opportunities for 2025-2034

    In-Depth Insights into the Cell And Gene Therapy Clinical Trial Services Market: Growth, Trends, and Opportunities for 2025-2034

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    How has the cell and gene therapy clinical trial services market grown in recent years?

    The cell and gene therapy clinical trial services market has seen rapid growth in recent years. It will grow from $3.79 billion in 2024 to $4.2 billion in 2025, with a compound annual growth rate (CAGR) of 10.7%. This growth is driven by the rising prevalence of chronic diseases, the demand for treatments for rare genetic disorders, increased funding for regenerative medicine research, better understanding of molecular disease mechanisms, and the increasing recognition of personalized medicine.

    How is the cell and gene therapy clinical trial services market size expected to evolve during the forecast period?

    The cell and gene therapy clinical trial services market is expected to reach $6.22 billion by 2029 with a CAGR of 10.3%. Growth is driven by the rise in genetic and autoimmune diseases, increased funding for gene therapy, the adoption of novel technologies, and growing genetic defects. Trends include AI and machine learning adoption, personalized medicine, and advancements in gene therapies.

    Get your cell and gene therapy clinical trial services market report here!

    https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

    Which key drivers are propelling the cell and gene therapy clinical trial services market’s growth?

    The rising incidence of genetic diseases is expected to drive the growth of the cell and gene therapy clinical trial services market. Genetic diseases are caused by variations in DNA or genetic composition, and their prevalence is rising due to factors like increased genetic testing and consanguineous marriages. Clinical trial services for cell and gene therapies are key in developing new treatments for genetic disorders. For example, in July 2022, the Cystic Fibrosis Foundation reported that cystic fibrosis affects nearly 40,000 people in the U.S., and over 105,000 people globally. The growing incidence of genetic diseases is propelling the market forward.

    What are the market segments in the cell and gene therapy clinical trial services industry?

    The cell and gene therapy clinical trial services market covered in this report is segmented –

    1) By Service: Clinical Trial Design And Planning, Supply And Logistic Services, Regulatory Affairs And Compliance, Data Management And Biostatics, Site Management And Monitoring, Other Services

    2) By Therapy Type: Gene Therapy, Cell Therapy, Gene Modified Cell Therapy

    3) By Indication: Oncology, Hematology, Metabolic Disorders, Infectious Diseases, Neurology, Cardiovascular Diseases, Musculoskeletal Disorders, Other Indications

    4) By End-Use: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic And Research Institutes, Other End-Users

    Subsegments:

    1) By Clinical Trial Design And Planning: Protocol Development, Trial Feasibility Studies, Trial Design Consultation, Patient Recruitment And Enrollment Strategy, Risk-Based Monitoring Plans

    2) By Supply And Logistic Services: Clinical Trial Supply Chain Management, Cold Chain Logistics, Packaging And Labeling Services, Transportation And Distribution Of Biological Samples, Customs And Import/Export Services

    3) By Regulatory Affairs And Compliance: Regulatory Strategy And Consulting, Regulatory Submission And Documentation, Compliance With GMP (Good Manufacturing Practices), Regulatory Pathway Consultation, Clinical Trial Applications (CTAs)

    4) By Data Management And Biostatistics: Clinical Data Management (CDM), Statistical Analysis And Reporting, Clinical Data Monitoring, Data Integration And Validation, Electronic Data Capture (EDC) Solutions

    5) By Site Management And Monitoring: Site Selection And Initiation, Clinical Monitoring And Site Visits, Patient Recruitment And Retention, Site Training And Support, Site Performance Monitoring

    6) By Other Services: Patient Advocacy And Engagement, Real-World Evidence (RWE) Studies, Post-Trial Services, Medical Writing And Documentation, Clinical Trial Auditing And Inspection

    Get your free sample now – explore exclusive market insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=15535&type=smp

    Which leading companies are shaping the growth of the cell and gene therapy clinical trial services market?

    Major companies operating in the cell and gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, IQVIA, Laboratory Corporation of America Holdings, ICON plc, Syneos Health Inc., Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Parexel International Corporation, PRA Health Sciences Inc., Covance Inc., Medpace Holdings Inc., BioClinica Inc., Precision Medicine Group LLC, Worldwide Clinical Trials LLC, Clinigen Group plc, Evidera Inc., Advarra LLC, Veristat LLC, Clinipace Inc., Celonic AG, Cromsource Inc., Novotech Pty Ltd., MedSource Holdings Inc., Frontage Laboratories Inc.

    What key trends are currently impacting the cell and gene therapy clinical trial services market’s development?

    In the cell and gene therapy clinical trial services market, companies are implementing advanced technologies, such as customer relationship management (CRM) systems, to streamline processes and improve efficiency. For example, in April 2023, AmerisourceBergen Corporation, a US-based healthcare company, launched the Cell and Gene Therapy (CGT) Integration Hub, which leverages CRM technology to enhance connectivity and simplify the therapy development process. The platform aims to improve patient and provider experiences by offering real-time tracking, expedited benefits investigation, and proactive alerts.

    Unlock exclusive market insights – purchase your research report now for a swift delivery!

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15535

    Which geographic areas are influencing the growth of the cell and gene therapy clinical trial services market?

    North America was the largest region in the cell and gene therapy clinical trial services market in 2023. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Similar Reports By The Business Research Company:

    Cell Isolation Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/cell-isolation-global-market-report

    Cell Therapy Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

    Cell Lysis And Fractionation Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/cell-lysis-and-fractionation-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Cell and Gene Therapy Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities

    Cell and Gene Therapy Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    How has the cell and gene therapy market grown over the years?

    The dimensions of the cell and gene therapy market have seen a rapid expansion in the past few years. The market size is projected to rise from $12.01 billion in 2024 to $15.48 billion in 2025, marking a compound annual growth rate (CAGR) of 28.9%. The remarkable growth during the historic period is a result of factors such as growing investments in cell and gene therapies, proliferation in research and development efforts, breakthroughs in cancer drug discovery, ascension in public-private associations, sturdy economic progression in developing markets, increased spending in healthcare, and the escalation in financial outlays for pharmaceutical R&D.

    What Is the forecasted market size and growth rate for the cell and gene therapy market?

    In the coming years, the cell and gene therapy market is set to experience swift expansion, projected to reach $29.15 billion in 2029 at a compound annual growth rate (CAGR) of 17.1%. The predicted expansion during this period is due to a confluence of factors such as the escalating prevalence of cancer and chronic diseases, the increasing number of older adults, a greater emphasis on cell and gene therapy, and a rise in healthcare spending. Key trends forecasted for this period encompass emphasis on progressive treatments like chimeric antigen receptor (CAR) T-cell therapy, dedication towards diverse research initiatives and securing funding, execution of key collaborations for the assimilation of cutting-edge technology, focus on crafting gene or genome editing tools particularly CRISPR, acquisition or partnership with rival companies, augmenting the quantity of pipeline studies to advance cell and gene therapies, and investment in the expansion of manufacturing premises.

    Get your cell and gene therapy market report here!

    https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

    What are the major factors driving growth in the cell and gene therapy market?

    The continuous contribution of investments and the amalgamation in cell and gene therapies significantly fueled the cell and gene therapy (CGT) market’s growth. Recognizing the CGT market’s potential, 16 of the top 20 biopharmaceutical firms in terms of revenue incorporated CGT products into their offerings. For example, the BioIndustry Association (BIA), a UK-based entity representing the biotech and life sciences industry, stated that in 2023, over 55% of the venture capital funds obtained by European companies were secured by UK cell and gene therapy firms. The UK typically accounts for approximately one-third of all VC investments in life sciences throughout Europe, which underscores the robust status of its cell and gene therapy sector. Consistent investments and consolidation in CGT production capacity contributed to a surge in production capabilities, thus fostering market growth. For instance, Purespring Therapeutics, a UK-based biotech firm, received $105 million funding in October 2024 to back the development of gene therapies for kidney diseases, such as running a phase 1/2 trial for an experimental treatment for immunoglobulin A nephropathy (IgAN). Purespring employs adeno-associated viruses (AAVs) to deliver its gene therapies to the body.

    What key areas define the segmentation of the global cell and gene therapy Market?

    The cell and gene therapy market covered in this report is segmented –

    1) By Product: Cell Therapy, Gene Therapy

    2) By Application: Oncology, Neurological Disorders, Other Applications

    3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

    Subsegments:

    1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy

    2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

    Get your free sample now – explore exclusive market insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

    What are the top market players propelling the growth of the cell and gene therapy industry?

    Major companies operating in the cell and gene therapy market include Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Biocon, Cipla, Stempeutics Research Pvt. Ltd., EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Oxford Biomedica plc, Santen Pharmaceutical Co., Therapeutic Innovation Australia, Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, inStem, Lonza, Nikon CeLL innovation Co. Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Oxford BioTherapeutics, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca

    What are the key trends shaping the future of the cell and gene therapy market?

    The cell and gene therapy (CGT) market is being significantly impacted by the advancement of Chimeric antigen receptor (CAR) T-cell therapy. This innovative therapy merges cell and gene therapy, involving the extraction of T cells from the patient’s bloodstream and their subsequent genetic modification to produce altered receptors, termed as chimeric antigen receptors (CARs), on their exteriors. These genetically restructured T cells, with their unique receptor structures, are then reintroduced into the patient’s body. The specialized receptors on these T cells then target the surface antigen of the cancer cells, culminating in the eradication of tumor cells. For example, in June 2022, Bristol-Myers Squibb Company, an American pharmaceutical corporation, obtained approval from the US Food and Drug Administration (US FDA) for their CAR T cell therapy Breyanzi, intended for use in adult patients suffering from large B-cell lymphoma (LBCL) including diffuse large B-cell lymphoma. Breyanzi, a unique CAR T cell therapy, utilizes the patient’s re-engineered T cells and reintroduces them into the body through a single-session treatment.

    Unlock exclusive market insights – purchase your research report now for a swift delivery!

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3472

    What regions are dominating the cell and gene therapy market growth?

    North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Browse Through More Similar Reports By The Business Research Company:

    nucleic acid based gene therapy market, global nucleic acid based gene therapy market, nucleic acid based gene therapy market trends, nucleic acid based gene therapy market forecast, nucleic acid based gene therapy market analysis, nucleic acid-based therapeutics market, nucleic acid based gene therapy global market report 2021, nucleotide therapy market, gene therapy industry report, nucleic acid based gene therapy market report 2020

    https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market

    Alpha Mannosidosis Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report

    Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2031

    https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-market

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Cell And Gene Therapy Clinical Trial Services Market Forecast and Analysis: Key Insights into Growth, Trends, and Emerging Opportunities

    Cell And Gene Therapy Clinical Trial Services Market Forecast and Analysis: Key Insights into Growth, Trends, and Emerging Opportunities

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    How Will the Growth Rate of the Cell And Gene Therapy Clinical Trial Services Market Shape Industry Trends by 2034?

    There has been impressive growth in recent years in the market size of clinical trial services for cell and gene therapy. The market, which will expand from $3.79 billion in 2024 to $4.2 billion in 2025, is expected to witness a compound annual growth rate (CAGR) of 10.7%. This growth during the historic period can be traced back to an elevated incidence of chronic diseases, a heightened demand for successful treatments for rare genetic conditions, an increase in government funding towards regenerative medical research, an expanded comprehension of the molecular mechanisms of various diseases, and enhanced awareness in personalized medicine’s potential.

    The market size of clinical trial services for cell and gene therapy is projected to undergo significant expansion in the coming years, anticipated to reach $6.22 billion by 2029, with a compound annual growth rate (CAGR) of 10.3%. This predicted growth during the projection period is due to the surge in worldwide cases of genetic and autoimmune diseases, increasing funds from the public and private sectors towards gene therapy research, the uptake of groundbreaking technologies, and an increase in genetic defects. Emerging trends within the forecast period consist of the integration of Artificial Intelligence, the employment of machine learning, the adoption of personalized medication, technological progressions, and gene therapies.

    What Are the Primary Drivers Supporting the Growth of the Cell And Gene Therapy Clinical Trial Services Market?

    The cell and gene therapy clinical trial services market growth is set to be spurred on by the escalating incidence of genetic diseases. These diseases are triggered by alterations in an individual’s DNA or genetic makeup. Various factors, such as increased genetic testing availability, the frequency of genetic mutations, and commonality of consanguineous marriages, are behind the rising prevalence of these diseases. The market for cell and gene therapy clinical trial services responds to this surge by fostering the creation of innovative treatments, personalizing therapies to each patient, hastening the conversion of research into clinical application, and widening the choices for patients plagued by genetic disorders. For instance, the Cystic Fibrosis (CF) Foundation, a not-for-profit organization based in the USA, reported a significant rise in cystic fibrosis cases in July of 2022. The disease affected close to 40,000 children and adults in the United States in 2022, with the global count exceeding 105,000 diagnosed cases. Therefore, the escalating incidence of genetic diseases is fueling the expansion of the cell and gene therapy clinical trial services market.

    Request Your Free Cell And Gene Therapy Clinical Trial Services Market Report Sample Now!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=15535&type=smp

    Who Are the Key Market Players Influencing the Growth of the Cell And Gene Therapy Clinical Trial Services Industry?

    Major companies operating in the cell and gene therapy clinical trial services market are:

    • Thermo Fisher Scientific Inc.

    • Sharp Services LLC

    • IQVIA

    • Laboratory Corporation of America Holdings

    • ICON plc

    What Key Market Trends Are Shaping the Future of the Cell And Gene Therapy Clinical Trial Services Industry?

    Noteworthy corporations within the cell and gene therapy clinical trial services market are directing their resources towards implementing sophisticated technology inclusive of customer relationship management system technology. This strategy aims to boost efficiency and secure a competitive edge in the market. The customer relationship management system adopted by these services optimizes and orchestrates communications with trial participants, healthcare providers, and other stakeholders throughout the clinical trial course. For example, AmerisourceBergen Corporation, a healthcare firm based in the US, unveiled the Cell and Gene Therapy (CGT) Integration Hub in April 2023. This platform seeks to enhance connectivity and expedite processes across the treatment pathway of cell and gene therapy. It is supported by AmerisourceBergen’s customer relationship management (CRM) system and aims to streamline the path-to-care process by extending superior visibility to doctors and patient services teams over the therapy development and delivery process. The CGT Integration Hub, equipped with features like accelerated benefits investigation, real-time status tracking, and proactive alerts, aspires to simplify care coordination, reduce hurdles, and enhance the overall patient and provider experience in delivering cell and gene therapies.

    Pre-order Your Report for Quick and Easy Delivery!

    https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

    How Are Key Segments Defining the Competitive Landscape of the Cell And Gene Therapy Clinical Trial Services Market?

    The cell and gene therapy clinical trial services market covered in this report is segmented –

    1) By Service: Clinical Trial Design And Planning, Supply And Logistic Services, Regulatory Affairs And Compliance, Data Management And Biostatics, Site Management And Monitoring, Other Services

    2) By Therapy Type: Gene Therapy, Cell Therapy, Gene Modified Cell Therapy

    3) By Indication: Oncology, Hematology, Metabolic Disorders, Infectious Diseases, Neurology, Cardiovascular Diseases, Musculoskeletal Disorders, Other Indications

    4) By End-Use: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic And Research Institutes, Other End-Users

    Subsegments:

    1) By Clinical Trial Design And Planning: Protocol Development, Trial Feasibility Studies, Trial Design Consultation, Patient Recruitment And Enrollment Strategy, Risk-Based Monitoring Plans

    2) By Supply And Logistic Services: Clinical Trial Supply Chain Management, Cold Chain Logistics, Packaging And Labeling Services, Transportation And Distribution Of Biological Samples, Customs And Import/Export Services

    3) By Regulatory Affairs And Compliance: Regulatory Strategy And Consulting, Regulatory Submission And Documentation, Compliance With GMP (Good Manufacturing Practices), Regulatory Pathway Consultation, Clinical Trial Applications (CTAs)

    4) By Data Management And Biostatistics: Clinical Data Management (CDM), Statistical Analysis And Reporting, Clinical Data Monitoring, Data Integration And Validation, Electronic Data Capture (EDC) Solutions

    5) By Site Management And Monitoring: Site Selection And Initiation, Clinical Monitoring And Site Visits, Patient Recruitment And Retention, Site Training And Support, Site Performance Monitoring

    6) By Other Services: Patient Advocacy And Engagement, Real-World Evidence (RWE) Studies, Post-Trial Services, Medical Writing And Documentation, Clinical Trial Auditing And Inspection

    Which Regions Are Emerging as Leaders in the Cell And Gene Therapy Clinical Trial Services Market?

    North America was the largest region in the cell and gene therapy clinical trial services market in 2023. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Defines the Scope of the Cell And Gene Therapy Clinical Trial Services Market?

    Cell and gene therapy clinical trial services refer to specialized services offered by contract research organizations (CROs) or clinical trial management corporations to facilitate the design, implementation, and management of clinical trials for cell and gene therapies. These services, which range from protocol design and patient recruiting to regulatory compliance and data administration, serve as the foundation for trials to progress smoothly, ensuring precision, efficacy, and adherence to high standards.

    Browse Through More Similar Reports By The Business Research Company:

    Cell Isolation Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/cell-isolation-global-market-report

    Cell Therapy Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

    Cell Lysis And Fractionation Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/cell-lysis-and-fractionation-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • The Road Ahead for the Cell and Gene Therapy Market: Key Growth Trends and Opportunities to Watch

    The Road Ahead for the Cell and Gene Therapy Market: Key Growth Trends and Opportunities to Watch

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    What CAGR is Anticipated for the Cell and Gene Therapy Market During the Forecast Period, and Why?

    The cell and gene therapy market size has expanded exponentially in recent years. It is forecasted to rise from $12.01 billion in 2024 to $15.48 billion in 2025, with a remarkable CAGR of 28.9%. The key drivers of past growth include increased investment in cell and gene therapies, advancements in research and development, breakthroughs in cancer drug discovery, a rise in public-private collaborations, strong economic growth in emerging markets, greater healthcare expenditures, and an increase in pharmaceutical R&D spending.

    The cell and gene therapy market is expected to grow rapidly, reaching $29.15 billion by 2029, with a CAGR of 17.1%. Growth is attributed to the rising prevalence of cancer and chronic diseases, aging populations, and increased healthcare spending. Key trends include advanced therapies like CAR T-cell therapy, research funding, gene editing tools, strategic partnerships, and expanding pipeline studies.

    How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the cell and gene therapy Market?

    The steady investment and consolidation in cell and gene therapies are contributing to the growth of the cell and gene therapy (CGT) market. Biopharmaceutical companies are increasingly investing in CGT, with 16 out of the 20 largest companies adding CGT products to their portfolios. For instance, UK-based Purespring Therapeutics received $105 million in funding in October 2024 to support the development of gene therapies. This investment in CGT production capacity is driving the market’s growth.

    Request Your Free Cell and Gene Therapy Market Report Sample Now!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

    Which Companies Are Poised to Shape the Future of the Cell and Gene Therapy Market?

    Major companies operating in the cell and gene therapy market include:

    • Biogen Inc._x000D_

    • Novartis AG_x000D_

    • Gilead Sciences_x000D_

    • Ionis Pharmaceuticals Inc._x000D_

    • Alnylam Pharmaceuticals Inc._x000D_

    What Are the Latest Innovations and Trends Influencing the Cell and Gene Therapy Market?

    In the cell and gene therapy (CGT) market, chimeric antigen receptor (CAR) T-cell therapy is making significant strides. CAR-T therapy involves genetically modified T cells to target cancer cells. For example, in June 2022, Bristol-Myers Squibb received U.S. FDA approval for Breyanzi, a CAR T-cell therapy for large B-cell lymphoma. This therapy is made from a patient’s own T cells, which are genetically engineered to target cancer cells effectively.

    Pre-order Your Report for Quick and Easy Delivery!

    https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

    Which Industry Segments Are Leading the Development and Expansion of the Cell and Gene Therapy Market?

    The cell and gene therapy market covered in this report is segmented –

    1) By Product: Cell Therapy, Gene Therapy

    2) By Application: Oncology, Neurological Disorders, Other Applications

    3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

    Subsegments:

    1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy

    2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

    What Regions Are Contributing Significantly to the Growth of the Cell and Gene Therapy Market?

    North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    How Is the Scope and Reach of the Cell and Gene Therapy Market Defined?

    Gene therapy involves the transmission of genetic material, typically in the form of a carrier or vector, and the uptake of the gene into the proper body cells. Cell therapy includes introducing cells into the patient with the appropriate function. Some procedures combine cell therapy with gene therapy.

    Browse Through More Similar Reports By The Business Research Company:

    nucleic acid based gene therapy market, global nucleic acid based gene therapy market, nucleic acid based gene therapy market trends, nucleic acid based gene therapy market forecast, nucleic acid based gene therapy market analysis, nucleic acid-based therapeutics market, nucleic acid based gene therapy global market report 2021, nucleotide therapy market, gene therapy industry report, nucleic acid based gene therapy market report 2020

    https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market

    Alpha Mannosidosis Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report

    Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2031

    https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-market

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on: